Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso
| Autor: | Halidou Tinto, Laeticia C. Toe, Coulibaly, Joel Tarning, Innocent Valea, Jean-Pierre Van Geertruyden, Maminata Traore, Geraint Davies, Umberto D'Alessandro, Niklas Lindegardh, Stephen A. Ward |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Microbiology (medical) medicine.medical_specialty Adolescent medicine.medical_treatment Artesunate Dihydroartemisinin Pharmacology Antimalarials Plasma Young Adult chemistry.chemical_compound Pharmacokinetics Pregnancy Burkina Faso Humans Medicine Pharmacology (medical) Malaria Falciparum Pregnancy Complications Infectious Young adult Biology Original Research biology business.industry Mefloquine Obstetrics Pharmacology. Therapy Plasmodium falciparum medicine.disease biology.organism_classification Artemisinins Drug Combinations Infectious Diseases chemistry Female Human medicine business Malaria medicine.drug |
| Zdroj: | The journal of antimicrobial chemotherapy |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dku154 |
| Popis: | Objectives Mefloquine/artesunate has recently been developed as a fixed-dose combination, providing a promising rescue/alternative treatment for malaria during pregnancy. However, limited data are available on the effect of pregnancy on its pharmacokinetic properties. This study was conducted to assess the pharmacokinetic properties of mefloquine/carboxymefloquine and artesunate/dihydroartemisinin in pregnant and non-pregnant women with uncomplicated malaria. Methods Twenty-four women in their second and third trimesters of pregnancy and 24 paired non-pregnant women were enrolled. All patients were treated for uncomplicated Plasmodium falciparum malaria with a standard fixed-dose combination of oral mefloquine and artesunate one daily over 3 days. Frequent blood samples were collected before treatment and at scheduled times post-dose for the drug measurements and pharmacokinetic analyses. The study was registered at www.clinicaltrials.gov (identifier: NCT00701961). Results The total median exposure to mefloquine and dihydroartemisinin was not significantly different between the pregnant and non-pregnant women (P > 0.05). There was a trend of higher exposure to mefloquine in the pregnant women, but this difference did not reach statistical significance (656 700 versus 542 400 h × ng/mL; P = 0.059). However, the total exposure to carboxymefloquine was 49% lower during pregnancy (735 600 versus 1 499 000 h × ng/mL; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|